ReviewCurrent opinion in immunology2022
ILC2s - development, divergence, dispersal.
Review in Current opinion in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Review
- Neuromedin U Activation of Group 2 Innate Lymphocytes Exacerbates Local Inflammation of Nasal Mucosa in Allergic Rhinitis.Allergy, asthma & immunology research · 2025Article
- Update on type 2 immunity.The Journal of allergy and clinical immunology · 2025Review
- Maternal influences on offspring food allergy.Immunological reviews · 2024Review
- Stage-specific GATA3 induction promotes ILC2 development after lineage commitment.Nature communications · 2024Article
- White-to-Beige and Back: Adipocyte Conversion and Transcriptional Reprogramming.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Dietary fiber is a critical determinant of pathologic ILC2 responses and intestinal inflammation.The Journal of experimental medicine · 2024Article
- Analysis of lipid uptake, storage, and fatty acid oxidation by group 2 innate lymphoid cells.Frontiers in immunology · 2024Article
- Metabolism in type 2 immune responses.Immunity · 2023Review
- The aryl hydrocarbon receptor instructs the immunomodulatory profile of a subset of Clec4a4Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Potential correlation of allograft infiltrating group 2 innate lymphoid cells with acute rejection after liver transplantation.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Over the last decade, we have come to appreciate group 2 innate lymphoid cells (ILC2s) as important players in host and tissue immunity. New studies of ILC2s and their precursors using novel reporter mice, advanced microscopy, and multi-omics approaches have expanded our knowledge on how these cells contribute to tissue physiology and function. This review highlights recent literature on this enigmatic cell, and we organize our discussion across three important paradigms in ILC2 biology: development, divergence, and dispersal. In addition, we frame our discussion in the context of other innate and adaptive immune cells to emphasize the relevance of expanding knowledge of ILC2s and tissue immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.